Coagulation Disorders in the ICU

Clinics in Chest Medicine

Volumn 30, Issue 1, 2009, Pages 123-129

  Marks, Peter W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Hemorrhage; Thrombocytopenia; Thrombosis; Transfusion

Indexed keywords

AMINOCAPROIC ACID; ANTIVITAMIN K; ARGATROBAN; CALCINEURIN INHIBITOR; CLOPIDOGREL; CONJUGATED ESTROGEN; COUMARIN; CYCLOSPORIN A; DABIGATRAN ETEXILATE; DESMOPRESSIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TACROLIMUS; VITAMIN K GROUP; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ALLERGIC REACTION; AMNION FLUID; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; CRYOPRECIPITATE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEMOLYTIC UREMIC SYNDROME; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INFECTION; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LOW DRUG DOSE; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; REPEATED DRUG DOSE; REVIEW; THROMBECTOMY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UREMIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; BLOOD TRANSFUSION; CRITICAL CARE; DIAGNOSIS, DIFFERENTIAL; HEMORRHAGE; HEMOSTASIS; HUMANS; INTENSIVE CARE UNITS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 58849120165     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2008.11.003     Document Type: Review

References (34)

1. Furie B., and Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med 326 12 (1992) 800-806
2. Gomez K., McVey J.H., and Tuddenham E. Inhibition of coagulation by macromolecular complexes. Haematologica 90 11 (2005) 1570-1576
3. Kamal A.H., Tefferi A., and Pruthi R.K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82 7 (2007) 864-873
4. Halevy D., Radhakrishnan J., Markowitz G., et al. Thrombotic microangiopathies. Crit Care Clin 18 2 (2002) 309-320
5. Vesey J.M., and Otto C.M. Complications of prosthetic heart valves. Curr Cardiol Rep 6 2 (2004) 106-111
6. George J.N. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med 22 2 (2007) 82-91
7. Zakarija A., Bandarenko N., Pandey D.K., et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the food and drug administration. Stroke 35 2 (2004) 533-537
8. Medina P.J., Sipols J.M., and George J.N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8 5 (2001) 286-293
9. Zheng X.L., and Sadler J.E. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 3 (2008) 249-277
10. Michael M., Elliott E.J., Craig J.C., et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis (2008 Oct 23) [Epub ahead of print]
11. Levi M. Disseminated intravascular coagulation. Crit Care Med 35 9 (2007) 2191-2195
12. Stafford I., and Sheffield J. Amniotic fluid embolism. Obstet Gynecol Clin North Am 34 3 (2007) 545-553
13. Aster R.H., and Bougie D.W. Drug-induced immune thrombocytopenia. N Engl J Med 357 6 (2007) 580-587
14. Bream-Rouwenhorst H.R., Hobbs R.A., and Horwitz P.A. Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation. J Interv Cardiol 21 4 (2008) 350-356
15. Lozano M., and Cid J. Consensus and controversies in platelet transfusion: trigger for indication, and platelet dose. Transfus Clin Biol 14 6 (2007) 504-508
16. Mannucci P.M., and Levi M. Prevention and treatment of major blood loss. N Engl J Med 356 22 (2007) 2301-2311
17. Kalmadi S., Tiu R., Lowe C., et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 107 1 (2006) 136-140
18. Hedges S.J., Dehoney S.B., Hooper J.S., et al. Evidence-based recommendations for uremic bleeding. Nat Clin Pract Nephrol 3 3 (2007) 138-153
19. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133 6 Suppl (2008) 160S-198S
20. Dentali F., Ageno W., and Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 4 9 (2006) 1853-1863
21. Wiedermann C.J., and Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res 122 Suppl. 2 (2008) S13-S18
22. Pabinger I., Brenner B., Kalina U., et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6 4 (2008) 622-631
23. Freeman W.D., Brott T.G., Barrett K.M., et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79 12 (2004) 1495-1500
24. Segal J.B., Dzik W.H., and Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 45 9 (2005) 1413-1425
25. Dara S.I., Rana R., Afessa B., et al. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med 33 11 (2005) 2667-2671
26. Birchall J., Stanworth S.J., Duffy M.R., et al. Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia. Transfus Med Rev 22 3 (2008) 177-187
27. Bates S.M., and Ginsberg J.S. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 351 3 (2004) 268-277
28. Tapson V.F. Acute pulmonary embolism. N Engl J Med 358 10 (2008) 1037-1052
29. Lentine K.L., Flavin K.E., and Gould M.K. Variability in the use of thromboprophylaxis and outcomes in critically ill medical patients. Am J Med 118 12 (2005) 1373-1380
30. Zamanian R.T., and Gould M.K. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med 14 5 (2008) 422-426
31. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112 3 (2005) 416-422
32. Arepally G.M., and Ortel T.L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 8 (2006) 809-817
33. Di Nisio M., Middeldorp S., and Büller H.R. Direct thrombin inhibitors. N Engl J Med 353 10 (2005) 1028-1040
34. Hirsh J., O'Donnell M., and Eikelboom J.W. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116 5 (2007) 552-560